Copyright
©The Author(s) 2022.
World J Clin Cases. Mar 6, 2022; 10(7): 2184-2193
Published online Mar 6, 2022. doi: 10.12998/wjcc.v10.i7.2184
Published online Mar 6, 2022. doi: 10.12998/wjcc.v10.i7.2184
Ref. | Sample size | Gender (male) | Age (median, range), years | Country | Stage | Number of colon carcinoma | Treatment | Tumor type | Threshold | Endpoints | NOS |
Cintin et al[20], 1999 | 603 | 355 | 69 (33-91) | Denmark | Duke A-D | 355 | Surgery | CRC | 247 ug/L (upper 95th percentile) | OS | 7 |
Cintin et al[21], 2002 | 324 | 192 | 68 (37-90) | Denmark | Duke A-D | 197 | Surgery | CRC | 247 ug/L (upper 95th percentile) | OS, PFS | 7 |
Liu et al[24], 2014 | 86 | 48 | 60 (38-76) | China | TNMI I-IV | 34 | Surgery | CRC | 216 ng/mL (median) | PFS | 6 |
Tarpgaard et al[27], 2014 | 510 | 301 | NR | Denmark | TNM IV | 302 | Non-surgery | CRC | 155 ug/L (upper 95th percentile) | OS, PFS | 7 |
Fuksiewicz et al[22], 2018 | 83 | 59 | 65 (25-82) | Poland | TNM I-III | NR | Surgery | RC | 44.6 pg/mL (upper 95th percentile) | OS, PFS | 6 |
Hermunen et al[23], 2020 | 147 | 75 | 60 (31-76) | Finland | TNM II-IV | 87 | Surgery | CRC | 70.7 ng/mL (maximum Youden’s index) | OS, PFS | 7 |
Peltonen et al[26], 2020 | 441 | 260 | 64.9 (33-84) | Denmark | TNM IV | 258 | Surgery (liver resection) | CRC | 34.8 ng/mL (upper 95th percentile) | OS, PFS | |
Oh et al[25], 2021 | 265 | 134 | NR | Korea | TNM I-IV | NR | Surgery | CRC | Positive in tumor cells | OS, PFS | 7 |
Yang et al[28], 2021 | 86 | 56 | 60.12 ± 7.32 (mean ± SD) | China | TNMI I-IV | 86 | Surgery | CC | Positive in tumor cells | OS | 7 |
No. of studies | HR | 95%CI | P value | I2 (%) | P value | |
Overall survival | 8 | 1.80 | 1.32-2.45 | < 0.001 | 90.3 | < 0.001 |
Treatment | ||||||
Surgery | 7 | 1.99 | 1.27-3.12 | 0.003 | 90.8 | < 0.001 |
Non-surgery | 1 | 1.17 | 1.05-1.30 | 0.004 | - | - |
Tumor type | ||||||
Colorectal carcinoma | 6 | 1.83 | 1.30-2.56 | < 0.001 | 92.9 | < 0.001 |
Rectal carcinoma | 1 | 0.69 | 0.04-11.45 | 0.796 | - | - |
Colon carcinoma | 1 | 1.81 | 1.13-2.90 | 0.013 | - | - |
Source of YKL-40 | ||||||
Serum | 6 | 1.83 | 1.26-2.66 | 0.001 | 92.7 | < 0.001 |
Tissue | 2 | 1.74 | 1.28-2.36 | < 0.001 | 0.0 | 0.816 |
Progression-free survival | 7 | 1.62 | 1.22-2.16 | 0.001 | 88.3 | < 0.001 |
Treatment | ||||||
Surgery | 6 | 1.93 | 1.21-3.08 | .005 | 87.8 | < 0.001 |
Non-surgery | 1 | 1.00 | 0.91-1.09 | 1.000 | - | - |
Tumor type | ||||||
Colorectal carcinoma | 6 | 1.64 | 1.22-2.20 | 0.001 | 90.2 | < 0.001 |
Rectal carcinoma | 1 | 1.32 | 0.39-4.46 | 0.655 | - | - |
Source of YKL-40 | ||||||
Serum | 6 | 1.54 | 1.15-2.07 | 0.004 | 88.0 | < 0.001 |
Tissue | 1 | 2.00 | 1.36-2.94 | < 0.001 | - | - |
- Citation: Wang J, Qi S, Zhu YB, Ding L. Prognostic value of YKL-40 in colorectal carcinoma patients: A meta-analysis. World J Clin Cases 2022; 10(7): 2184-2193
- URL: https://www.wjgnet.com/2307-8960/full/v10/i7/2184.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v10.i7.2184